A Comprehensive Monograph on Sulbactam: From β-Lactamase Inhibition to a Renewed Strategy Against Multidrug-Resistant Pathogens

Executive Summary

Sulbactam is a semi-synthetic, small-molecule drug belonging to the penicillanic acid sulfone class, identified by DrugBank ID DB09324 and CAS Number 68373-14-8. Initially developed as a β-lactamase inhibitor, its primary function is to irreversibly bind to and inactivate a wide range of bacterial β-lactamase enzymes, thereby protecting co-administered β-lactam antibiotics from degradation. This mechanism restores and expands the antibacterial spectrum of partners such as ampicillin and cefoperazone, making these combinations effective against numerous common pathogens.

Beyond this protective role, Sulbactam possesses a unique and clinically significant intrinsic antibacterial activity, particularly against Acinetobacter baumannii, a pathogen of critical global concern. This direct bactericidal effect is mediated through the inhibition of essential penicillin-binding proteins (PBPs), a characteristic that distinguishes it from many other β-lactamase inhibitors. This dual mechanism of action—acting as both a shield and a direct-acting agent—has facilitated Sulbactam's enduring relevance and recent resurgence in clinical practice.

Pharmacokinetically, Sulbactam is administered parenterally and exhibits a profile that is well-matched to its common partner, ampicillin, with a short half-life of approximately one hour and primary elimination via the kidneys. This synergy simplifies dosing, including necessary adjustments in patients with renal impairment.

Clinically, ampicillin/sulbactam (Unasyn®) is a widely used agent for treating skin, intra-abdominal, and gynecological infections. However, the most significant recent development is the strategic deployment of high-dose sulbactam regimens and the U.S. Food and Drug Administration (FDA) approval of sulbactam/durlobactam (Xacduro®) in 2023. This novel combination is specifically indicated for hospital-acquired and ventilator-associated bacterial pneumonia caused by carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRAB). The pivotal ATTACK trial demonstrated that sulbactam/durlobactam was not only non-inferior to colistin—a last-resort therapy—but also possessed a markedly superior safety profile, particularly concerning nephrotoxicity.

This report provides an exhaustive analysis of Sulbactam's physicochemical properties, pharmacology, clinical applications across its various formulations, safety profile, and global regulatory status. It further examines its crucial role in combating antimicrobial resistance and synthesizes findings from recent clinical trials that are reshaping its therapeutic positioning. Sulbactam's evolution from a supportive partner drug to a targeted, first-line agent against one of the most difficult-to-treat pathogens exemplifies a successful paradigm in antimicrobial development and underscores its critical position in the modern infectious disease armamentarium.

1.0 Introduction: The Enduring Relevance of a Classic β-Lactamase Inhibitor

The discovery of penicillin marked the dawn of the antibiotic era, fundamentally transforming the practice of medicine and saving countless lives. The β-lactam class of antibiotics, which includes penicillins and cephalosporins, rapidly became the cornerstone of antibacterial therapy due to their potent bactericidal activity and favorable safety profile.[1] However, the widespread use of these agents exerted immense selective pressure on bacterial populations, leading to the rapid evolution and dissemination of resistance mechanisms. Among the most clinically significant of these is the production of β-lactamase enzymes, which hydrolyze the amide bond in the characteristic four-membered β-lactam ring, rendering the antibiotic inactive.[1]

In response to this escalating threat, a key therapeutic strategy emerged: the combination of a β-lactam antibiotic with a β-lactamase inhibitor (BLI). These inhibitor compounds were designed to act as "sacrificial" partners, preferentially binding to and inactivating β-lactamases, thereby shielding the partner antibiotic and allowing it to reach its target—the penicillin-binding proteins (PBPs) involved in bacterial cell wall synthesis.[1] Sulbactam, a penicillanic acid sulfone patented in 1977 and approved for medical use in 1986, was one of the first-generation BLIs to enter clinical practice.[4] Its primary function was established as a "suicide inhibitor," forming an irreversible complex with a range of β-lactamases and restoring the in vitro and clinical activity of antibiotics like ampicillin and cefoperazone against resistant bacterial strains.[2]

While initially conceptualized as a supportive agent, Sulbactam's unique pharmacological profile has facilitated its clinical and developmental resurgence decades after its introduction. Unlike other early BLIs, Sulbactam possesses clinically relevant intrinsic antibacterial activity against a select group of pathogens, most notably the ESKAPE pathogen Acinetobacter baumannii, a frequent cause of severe nosocomial infections with alarmingly high rates of multidrug resistance.[7] This report posits that this dual functionality has driven a paradigm shift in Sulbactam's therapeutic role. The recent development of high-dose, extended-infusion regimens and the landmark 2023 FDA approval of sulbactam/durlobactam (Xacduro®) signify its evolution from a general-purpose shield to a targeted, indispensable weapon in the global fight against antimicrobial resistance.

2.0 Physicochemical Profile and Pharmaceutical Formulations

A comprehensive understanding of a drug's physicochemical properties is fundamental to its formulation, stability, and clinical application. Sulbactam is a well-characterized small molecule with distinct chemical and physical attributes.

2.1 Chemical Identification and Structure

Sulbactam is a semi-synthetic penicillinate sulfone, derived from the core penicillin nucleus, 6-aminopenicillanic acid.[7] Its structure is defined by the presence of the characteristic β-lactam ring fused to a thiazolidine ring, where the sulfur atom is oxidized to a sulfone group.

• Systematic (IUPAC) Name: (2S,5R)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide.[4]
• Common Synonyms: Penicillanic Acid Dioxide, Penicillanic acid sulfone, Betamaze, CP 45,899.[8]
• Key Identifiers:
• CAS Number: 68373-14-8 [10]
• DrugBank ID: DB09324 [8]
• PubChem CID: 130313 [4]
• European Community (EC) Number: 269-878-2 [5]
• ATC Code: J01CG01 [4]

The molecular formula of Sulbactam is $C_{8}H_{11}NO_{5}S$, corresponding to a molecular weight of approximately 233.24 g/mol.[4] Its precise chemical structure is often represented using standardized notations such as SMILES (CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O) and InChIKey (FKENQMMABCRJMK-RITPCOANSA-N) to ensure unambiguous identification in chemical databases.[4]

2.2 Physical and Pharmaceutical Properties

Sulbactam is typically supplied as a white to off-white or almost white crystalline powder.[10] It is characterized as being freely soluble in water and also exhibits solubility in organic solvents such as dimethylformamide (DMF), dimethyl sulfoxide (DMSO), and ethanol.[10] Its melting point is reported in the range of 148 °C to 156 °C, with decomposition occurring at these temperatures.[4]

Due to its chemical nature, Sulbactam is heat-sensitive and requires specific storage conditions, typically refrigeration at 2-8°C or freezing at temperatures below 0°C to maintain its stability and potency.[10]

2.3 Formulations

Given its poor oral bioavailability, Sulbactam is formulated exclusively for parenteral administration.[5] It is available as a sterile dry powder for reconstitution, intended for either intravenous (IV) or intramuscular (IM) injection.[16] It is most commonly available in combination products, either co-formulated in a single vial with ampicillin sodium (e.g., Unasyn®) or co-packaged as a kit with durlobactam (Xacduro®).[17]

Upon reconstitution with a suitable aqueous diluent (e.g., Sterile Water for Injection), the powder dissolves to form a pale yellow to yellow solution.[16] The pH of these reconstituted solutions is alkaline, typically ranging from 8.0 to 10.0.[16]

Table 1: Key Physicochemical Properties of Sulbactam

Property	Value	Source(s)
Systematic (IUPAC) Name	(2S,5R)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide	[4, 11]
CAS Number	68373-14-8	[13]
DrugBank ID	DB09324	[13]
Molecular Formula	$C_{8}H_{11}NO_{5}S$	[5, 13]
Molecular Weight	233.24 g/mol	[10, 14]
Appearance	White to off-white crystalline powder	[10, 12]
Solubility (Water)	Freely soluble	[12, 16]
Melting Point	148–156 °C (decomposes)	4
Storage Temperature	2–8°C or Frozen (<0°C)	[10, 12]

3.0 Comprehensive Pharmacological Profile

The clinical utility of Sulbactam is defined by its unique dual-function pharmacology, acting as both a potent β-lactamase inhibitor and a direct-acting antibacterial agent. Its pharmacokinetic profile is well-suited for combination therapy, particularly with ampicillin.

3.1 Mechanism of Action: A Dual-Function Molecule

Sulbactam's mechanism of action is twofold, a characteristic that sets it apart from many other β-lactamase inhibitors and underpins its modern clinical applications.

3.1.1 Irreversible β-Lactamase Inhibition

The primary and most well-known function of Sulbactam is its role as a competitive, irreversible inhibitor of a broad range of bacterial β-lactamase enzymes.[5] This mechanism is often referred to as "suicide inhibition" because the inhibitor is consumed in the process of inactivating the target enzyme.[4] The process unfolds in a stepwise manner. First, due to its structural analogy to penicillin, Sulbactam binds to the active site of the β-lactamase. This initial interaction is followed by the opening of Sulbactam's β-lactam ring, which leads to the formation of a stable, covalent acyl-enzyme intermediate complex. This complex is highly resistant to hydrolysis, effectively sequestering the enzyme and rendering it permanently inactive.[2]

By neutralizing these enzymes, Sulbactam protects co-administered β-lactam antibiotics from degradation, restoring their ability to reach their PBP targets and exert their bactericidal effects.[2] Sulbactam demonstrates good inhibitory activity against many of the most common plasmid-mediated Ambler class A β-lactamases (e.g., TEM-1, SHV variants) and some chromosomally mediated Ambler class C cephalosporinases.[3] However, its activity is limited against certain enzymes; it is noted to be less potent against TEM-2 and SHV-1 compared to clavulanate and tazobactam, and it is not effective against Ambler class B metallo-β-lactamases or certain Ambler class D oxacillinases.[7]

3.1.2 Intrinsic Antibacterial Activity

A defining feature of Sulbactam is its intrinsic, albeit weak-to-moderate, antibacterial activity.[5] This direct action is not dependent on a partner antibiotic and is mediated by Sulbactam's ability to bind to and inhibit essential bacterial PBPs, which are the transpeptidases responsible for the final steps of peptidoglycan synthesis in the bacterial cell wall.[23] The inhibition of these enzymes disrupts cell wall integrity, leading to cell lysis and death.[23]

This intrinsic activity is particularly pronounced and clinically relevant against a specific subset of bacteria, including Neisseriaceae, Bacteroides fragilis, and, most importantly, species within the genus Acinetobacter.[5] In Acinetobacter baumannii, Sulbactam preferentially binds to PBP1 and PBP3, key enzymes for cell wall elongation and septation, respectively.[4] This targeted activity is the pharmacological basis for the use of high-dose sulbactam-containing regimens as a primary therapy for infections caused by multidrug-resistant A. baumannii.

3.2 Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

The movement of Sulbactam through the body is well-characterized and predictable, with key features that make it an effective partner for parenteral β-lactam antibiotics.

• Absorption: Sulbactam is poorly absorbed from the gastrointestinal tract and therefore must be administered parenterally via the IV or IM route.[5] Following a 15-minute IV infusion, peak serum concentrations are achieved immediately.[5] For instance, after an IV dose of 1000 mg ampicillin plus 500 mg sulbactam, peak sulbactam serum levels range from 21 to 40 mcg/mL.[5] After an IM injection of the same dose, peak levels are lower, ranging from 6 to 24 mcg/mL.[5]
• Distribution: Sulbactam distributes extensively into most body tissues and extracellular fluids.[5] The steady-state volume of distribution is reported to be between 12.2 and 16.3 L.[5] It exhibits moderate reversible binding to human plasma proteins, at approximately 38%.[5] A critical distribution characteristic is its ability to penetrate the central nervous system. In the presence of meningeal inflammation, Sulbactam's penetration into the cerebrospinal fluid (CSF) is significantly enhanced, achieving concentrations as high as 32% of corresponding serum levels, which supports its therapeutic use in cases of bacterial meningitis.[5]
• Metabolism: The metabolism of Sulbactam has not been extensively characterized in the literature, which strongly suggests that it undergoes minimal to no metabolic transformation in the body.[5]
• Excretion: Sulbactam is rapidly eliminated from the body, primarily by the kidneys.[4] In individuals with normal renal function, approximately 75% to 85% of an administered dose is excreted unchanged in the urine within the first 8 hours.[5] The elimination half-life in healthy volunteers is short, approximately one hour.[4] This rapid renal clearance necessitates frequent dosing (e.g., every 6 hours) to maintain therapeutic concentrations.

The pharmacokinetic profile of Sulbactam is remarkably similar to that of its most common partner, ampicillin. Both drugs have a short half-life of about one hour and are predominantly cleared by the kidneys.[5] This parallel pharmacokinetic behavior is not a coincidence but a critical feature for the success of the combination product. In patients with impaired renal function, the elimination kinetics of both ampicillin and sulbactam are affected to a similar degree.[18] Consequently, the therapeutic ratio of ampicillin to sulbactam in the serum remains constant across a wide spectrum of renal function. This property greatly simplifies clinical management, as the dosing interval of the combination product can be adjusted based on creatinine clearance without unbalancing the synergistic relationship between the antibiotic and its protector. If one component were cleared at a different rate, the dosing interval would be complicated, and the therapeutic window could be compromised, with one drug potentially reaching sub-therapeutic or toxic levels relative to the other.

4.0 Clinical Efficacy and Therapeutic Applications Across Formulations

Sulbactam is exclusively used in clinical practice as part of a combination product. Its therapeutic applications are defined by the spectrum of the partner antibiotic, augmented by Sulbactam's ability to overcome β-lactamase-mediated resistance and, in some cases, by its own intrinsic activity.

4.1 Ampicillin/Sulbactam (Unasyn®)

The combination of ampicillin and sulbactam, typically in a 2:1 ratio, is a workhorse parenteral antibiotic in many healthcare settings. Its FDA-approved indications include the treatment of skin and skin structure infections, intra-abdominal infections, and gynecological infections caused by susceptible β-lactamase-producing organisms.[8] Its broad spectrum covers many Gram-positive cocci (e.g., methicillin-susceptible Staphylococcus aureus), Gram-negative bacilli (e.g., Haemophilus influenzae, Escherichia coli, Klebsiella species), and a wide range of anaerobic bacteria, including Bacteroides fragilis.[18]

Beyond its approved indications, ampicillin/sulbactam is widely used for numerous off-label and guideline-recommended applications. These include aspiration pneumonia, bone and joint infections, endocarditis, bacterial meningitis, sinusitis, and surgical prophylaxis.[8] It is also a recommended agent for the empiric treatment of infections resulting from animal or human bites, given its activity against common oral flora such as Pasteurella multocida, Eikenella corrodens, and anaerobes.[25]

4.2 Cefoperazone/Sulbactam

While not available in the United States, the combination of the third-generation cephalosporin cefoperazone with sulbactam is widely used internationally, often under brand names like Sulperazon®.[4] This combination is indicated for a broad range of infections, including those of the upper and lower respiratory and urinary tracts, peritonitis, cholecystitis, septicemia, and meningitis.[28] The addition of sulbactam extends the activity of cefoperazone to cover many β-lactamase-producing organisms. Retrospective clinical data suggest that cefoperazone/sulbactam is as effective as imipenem/cilastatin for the treatment of Acinetobacter bacteremia, highlighting the important contribution of the sulbactam component.[30] Reflecting its clinical importance, the World Health Organization (WHO) is considering reclassifying cefoperazone/sulbactam from its "Not Recommended" list to the "Watch" category of its AWaRe classification system, particularly for its role in treating infections caused by ESBL-producing Enterobacteriaceae.[31]

4.3 Sulbactam/Durlobactam (Xacduro®)

The most recent and targeted application of Sulbactam is in the combination product Xacduro®, which pairs it with durlobactam, a novel broad-spectrum diazabicyclooctane (DBO) β-lactamase inhibitor.[32] This combination was specifically developed to address the urgent threat of infections caused by carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRAB), a WHO Priority 1 pathogen.[33]

Durlobactam has potent activity against the serine-β-lactamases commonly produced by Acinetobacter, including Ambler class D oxacillinases (OXA), which can hydrolyze sulbactam.[19] By inhibiting these enzymes, durlobactam effectively "re-sensitizes" CRAB strains to Sulbactam, allowing Sulbactam to exert its intrinsic bactericidal activity via PBP inhibition.[32] In May 2023, the FDA approved Xacduro® for the treatment of adults with hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible isolates of A. baumannii-calcoaceticus complex.[4] This approval provides a much-needed, effective, and safer alternative to older, more toxic agents like colistin for these life-threatening infections.

4.4 Other Combinations and Intrinsic Activity Focus

Sulbactam is also found in combination with other β-lactams, such as amoxicillin and ceftriaxone, primarily in international markets, to treat infections caused by β-lactamase-producing bacteria.[8] A significant trend in modern infectious disease practice is the use of high-dose ampicillin/sulbactam not for its broad-spectrum coverage, but specifically to leverage the intrinsic anti-Acinetobacter activity of the sulbactam component.[7] This strategy is often employed as a carbapenem-sparing regimen or as part of a combination therapy for documented CRAB infections when newer agents like sulbactam/durlobactam are unavailable.

Table 2: Summary of Major Sulbactam Combination Products and Key Indications

Combination Product	Brand Name(s)	Partner Antibiotic	Primary Mechanism & Rationale	Key Approved/Guideline-Recommended Indications
Ampicillin/Sulbactam	Unasyn®	Ampicillin (Aminopenicillin)	Sulbactam inhibits β-lactamases, restoring ampicillin's activity against a broad range of Gram-positive, Gram-negative, and anaerobic bacteria.	Skin & soft tissue infections, intra-abdominal infections, gynecological infections, aspiration pneumonia, bite wounds, CRAB infections (high-dose).
Cefoperazone/Sulbactam	Sulperazon®	Cefoperazone (3rd-gen Cephalosporin)	Sulbactam expands cefoperazone's spectrum to include β-lactamase producers, enhancing activity against Gram-negatives, including Pseudomonas and Acinetobacter.	Respiratory tract infections, urinary tract infections, septicemia, meningitis, infections caused by ESBL-producing organisms.
Sulbactam/Durlobactam	Xacduro®	Durlobactam (β-Lactamase Inhibitor)	Durlobactam inhibits Acinetobacter's serine-β-lactamases (including OXA enzymes), protecting sulbactam and enabling its intrinsic bactericidal activity against CRAB.	Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible Acinetobacter baumannii-calcoaceticus complex.

5.0 Dosing, Administration, and Considerations in Specific Populations

The effective and safe use of sulbactam-containing products requires careful attention to dosing regimens, route of administration, and necessary adjustments for specific patient populations, particularly those with renal dysfunction.

5.1 Standard, High-Dose, and Extended-Infusion Regimens

Dosing strategies for sulbactam combinations have evolved significantly, reflecting a deeper understanding of pharmacokinetic/pharmacodynamic (PK/PD) principles. The efficacy of β-lactam antibiotics, including the direct action of sulbactam against Acinetobacter, is best predicted by the percentage of the dosing interval that the free drug concentration remains above the minimum inhibitory concentration (%fT>MIC).

• Ampicillin/Sulbactam (Unasyn®): The standard adult dosage is 1.5 g (1 g ampicillin/0.5 g sulbactam) to 3 g (2 g ampicillin/1 g sulbactam) administered IV or IM every 6 hours.[23] The total daily dose of sulbactam should generally not exceed 4 grams in this context.[23] However, for severe infections caused by less susceptible organisms like CRAB, this standard approach is often insufficient to achieve the necessary PK/PD targets. This has led to the adoption of high-dose, extended-infusion regimens. The 2022 Infectious Diseases Society of America (IDSA) guidelines recommend a dose of 9 g of ampicillin/sulbactam (containing 3 g of sulbactam) administered intravenously every 8 hours, with each dose infused over 4 hours.[23] This strategy maximizes the %fT>MIC, which is critical for overcoming resistance in pathogens with elevated MICs.
• Sulbactam/Durlobactam (Xacduro®): The approved adult dosage is 1 g of sulbactam and 1 g of durlobactam administered as a 3-hour IV infusion every 6 hours.[20] The extended infusion time is an integral part of the approved regimen, designed from the outset to optimize the PK/PD profile against the target pathogen.
• Administration Routes: Sulbactam combinations can be administered by slow IV injection (over 10–15 minutes), as an IV infusion (over 15–30 minutes for standard doses, or longer for extended infusions), or by deep intramuscular injection.[23]

The shift in clinical practice from standard intermittent bolus dosing to high-dose, extended infusions for severe infections is a direct application of advanced pharmacological principles. Early dosing regimens were established against highly susceptible bacteria, where achieving a %fT>MIC target of 40-50% was readily accomplished with rapid infusions. However, as clinicians began to rely on sulbactam's intrinsic activity against resistant pathogens like A. baumannii with higher MICs, it became clear that simply increasing the dose was not the most efficient strategy. PK/PD modeling demonstrated that for time-dependent antibacterials, prolonging the infusion duration is a more effective method of increasing the %fT>MIC than increasing the peak concentration. An extended infusion maintains the serum drug concentration above the pathogen's MIC for a much larger portion of the dosing interval, thereby maximizing the bactericidal effect. The IDSA's recommendations and the design of the Xacduro® regimen are direct consequences of this scientific understanding, representing a more sophisticated, pathogen-targeted approach to antibiotic dosing.

5.2 Dosing Adjustments in Renal Impairment

Since sulbactam and its partner antibiotics like ampicillin are primarily eliminated by the kidneys, dosage adjustments are mandatory in patients with renal impairment to prevent drug accumulation and potential toxicity. The standard approach is to extend the dosing interval while keeping the dose constant.

• For Ampicillin/Sulbactam:
• CrCl ≥30 mL/min: No dosage adjustment is necessary (e.g., 1.5–3 g q6h–q8h).[24]
• CrCl 15–29 mL/min: The dosing interval is extended to every 12 hours (e.g., 1.5–3 g q12h).[24]
• CrCl 5–14 mL/min: The dosing interval is extended to every 24 hours (e.g., 1.5–3 g q24h).[24]
• For Sulbactam/Durlobactam: Dosing adjustments are also required for both renal impairment (CrCl < 45 mL/min) and augmented renal clearance (CrCl ≥ 130 mL/min).[20]
• Hemodialysis: Both ampicillin and sulbactam are effectively removed by hemodialysis. Therefore, doses should be scheduled to be administered after a dialysis session to ensure therapeutic levels are maintained.[42]

5.3 Pediatric and Geriatric Dosing Considerations

• Pediatric Population: Dosing in children is typically based on body weight. For ampicillin/sulbactam in children 1 year of age or older, a common recommended dose is 300 mg/kg/day of the combination product (equivalent to 200 mg/kg/day of ampicillin and 100 mg/kg/day of sulbactam), administered IV in equally divided doses every 6 hours.[24] Children weighing 40 kg or more should receive standard adult doses.[23] Caution is advised in neonates, especially premature infants and those in the first week of life, due to their immature renal function, which can prolong the drug's half-life.[23]
• Geriatric Population: No specific dosage adjustments are required for elderly patients based on age alone.[17] However, because renal function often declines with age, it is crucial to assess renal function (e.g., by calculating creatinine clearance) and adjust the dosing regimen accordingly, as would be done for any adult patient with renal impairment.

6.0 Safety, Tolerability, and Risk Management

While generally well-tolerated, sulbactam-containing products are associated with a range of potential adverse effects, from common and mild to rare but severe. A thorough understanding of this safety profile, along with contraindications and drug interactions, is essential for safe clinical use.

6.1 Comprehensive Review of Adverse Drug Reactions

The adverse event profile of sulbactam is largely reflective of the aminopenicillin class, with some specific considerations.

• Common Adverse Effects: The most frequently reported side effects are gastrointestinal disturbances, including diarrhea, nausea, and vomiting.[43] Injection site reactions, such as pain, erythema, swelling, and thrombophlebitis, are also common with parenteral administration.[43] A non-allergic skin rash is also frequently observed.[44]
• Serious and Infrequent Adverse Effects:
• Hypersensitivity Reactions: As a β-lactam, sulbactam carries a risk of serious and occasionally fatal hypersensitivity (anaphylactic) reactions. These are more likely in individuals with a prior history of penicillin or cephalosporin allergy or a history of atopy. A careful allergy history is mandatory before initiating therapy.[16]
• Severe Cutaneous Adverse Reactions (SCARs): Rare but life-threatening skin reactions have been reported, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP). Any progressing skin rash warrants immediate discontinuation of the drug.[16]
• Hepatotoxicity: Drug-induced liver injury, including hepatitis and cholestatic jaundice, has been associated with the use of ampicillin/sulbactam. This toxicity is usually reversible, but fatalities have been reported. Regular monitoring of hepatic function is recommended, especially in patients with pre-existing liver impairment.[16]
• Clostridioides difficile-Associated Diarrhea (CDAD): The use of sulbactam-containing antibiotics can alter the normal colonic flora, leading to the overgrowth of C. difficile. This can result in a spectrum of illness from mild diarrhea to severe, life-threatening pseudomembranous colitis. CDAD can occur during therapy or up to two months after its completion.[17]
• Hematologic Effects: Rare cases of blood dyscrasias, including leukopenia, thrombocytopenia, and hemolytic anemia, have been reported.[45]

6.2 Absolute and Relative Contraindications

• Absolute Contraindications:
• A history of a serious hypersensitivity reaction (e.g., anaphylaxis, SJS) to any component of the formulation or to any other β-lactam antibiotic (penicillins, cephalosporins).[16]
• A history of cholestatic jaundice or hepatic dysfunction associated with a previous course of ampicillin/sulbactam.[17]
• Precautions and Relative Contraindications:
• Mononucleosis: Patients with infectious mononucleosis have a very high incidence of developing a non-allergic, pruritic, maculopapular rash when treated with aminopenicillins. Therefore, ampicillin/sulbactam should not be administered to these patients.[17]
• Renal Impairment: Patients with impaired renal function require dosage adjustments to avoid drug accumulation.[17]
• History of Gastrointestinal Disease: Use with caution in patients with a history of colitis, due to the risk of CDAD.[51]

6.3 Clinically Significant Drug and Disease State Interactions

• Drug-Drug Interactions:
• Probenecid: Competitively inhibits the renal tubular secretion of both ampicillin and sulbactam, resulting in higher and more prolonged serum concentrations. This interaction can be used therapeutically to boost levels but requires careful monitoring.[21]
• Allopurinol: The concurrent administration of allopurinol with ampicillin significantly increases the incidence of rash compared to ampicillin alone.[49]
• Anticoagulants (e.g., Warfarin): Penicillins may rarely affect platelet function and alter gut flora responsible for vitamin K synthesis, potentially potentiating the effects of anticoagulants.[17]
• Bacteriostatic Antibiotics (e.g., Tetracyclines, Macrolides): These agents may interfere with the bactericidal action of penicillins. Concurrent use is generally avoided unless synergy has been demonstrated.[17]
• Oral Contraceptives: Broad-spectrum antibiotics can alter the intestinal flora, potentially reducing the absorption and efficacy of oral estrogen-containing contraceptives.[17]
• Live Vaccines (e.g., Cholera Vaccine): The efficacy of live bacterial vaccines can be diminished by concurrent antibiotic use.[17]
• Disease State Interactions:
• In addition to the conditions listed under contraindications (colitis, mononucleosis, renal dysfunction), patients on sodium-restricted diets (e.g., those with congestive heart failure or hypertension) should be monitored. Parenteral formulations of ampicillin/sulbactam contain a significant amount of sodium (e.g., approximately 115 mg or 5 mEq per 1.5 g of Unasyn®).[16]

7.0 Sulbactam in the Context of Antimicrobial Resistance

Sulbactam's relationship with antimicrobial resistance is complex: it is a tool designed to combat resistance, yet bacteria can also develop resistance to it. Its most vital contemporary role is as a direct therapeutic agent against one of the world's most formidable resistant pathogens.

7.1 The Molecular Basis of Resistance to Sulbactam

While Sulbactam's primary function is to inhibit β-lactamases, bacteria have evolved mechanisms to evade its action.[2] In Acinetobacter baumannii, resistance can arise from specific mutations in the genes encoding its PBP targets, particularly pbp3. However, studies have shown that high-level resistance stemming from these mutations can impose a significant "fitness cost" on the bacterium, potentially limiting the clinical emergence and transmission of such strains.[9] Other described mechanisms of resistance include the upregulation of multidrug efflux pumps, which actively transport the drug out of the bacterial cell, and the production of β-lactamases that are not effectively inhibited by sulbactam, such as metallo-β-lactamases.[9]

In Gram-negative bacteria like Escherichia coli, resistance to the ampicillin/sulbactam combination is an increasing clinical problem. Prior exposure to penicillin-class antibiotics has been identified as a significant independent risk factor for the isolation of ampicillin/sulbactam-resistant E. coli.[54] Furthermore, some bacteria, such as those in the Enterobacter cloacae complex, possess inducible chromosomal AmpC β-lactamases. Even basal expression of these enzymes can confer intrinsic resistance to ampicillin/sulbactam.[55]

7.2 Sulbactam as a Primary Therapeutic Agent for Carbapenem-Resistant Acinetobacter baumannii (CRAB)

A. baumannii has emerged as a critical nosocomial pathogen, notorious for its ability to acquire resistance determinants to multiple antibiotic classes.[9] Carbapenem-resistant strains (CRAB) are of particular concern, designated as a "Priority 1: CRITICAL" pathogen by the WHO, as therapeutic options are severely limited.[9]

In this challenging landscape, Sulbactam's intrinsic bactericidal activity has positioned it as a key therapeutic agent. High-dose, extended-infusion regimens of ampicillin/sulbactam are recommended by guidelines to maximize the time that sulbactam concentrations exceed the MIC of the infecting CRAB isolate, thereby saturating the target PBPs and overcoming some resistance mechanisms.[39] The development of sulbactam/durlobactam was a direct strategic response to the limitations of sulbactam monotherapy. Many CRAB strains produce OXA-type carbapenemases that can also hydrolyze sulbactam. Durlobactam potently inhibits these enzymes, protecting sulbactam and restoring its efficacy, as evidenced by a 16- to 64-fold reduction in sulbactam MICs when the two are combined.[33]

7.3 Comparative Efficacy in Monomicrobial vs. Polymicrobial Infections

The treatment of severe infections, such as VAP, is often complicated by the presence of multiple pathogens. A recent multicenter retrospective study provided valuable data on the performance of sulbactam-based regimens in MDR A. baumannii pulmonary infections.[56] The study's findings challenged conventional clinical wisdom. It revealed that the microbial clearance rate of A. baumannii was significantly higher in patients with polymicrobial infections (e.g., co-infection with Klebsiella pneumoniae or Pseudomonas aeruginosa) compared to those with monomicrobial A. baumannii infections.[56]

This counterintuitive result suggests a more complex interplay between pathogens, the host immune system, and antibiotic therapy than is often assumed. While a polymicrobial infection presents a broader therapeutic challenge, the data indicate that the overall outcome regarding the clearance of the most resistant pathogen (A. baumannii) may be improved. Several factors could contribute to this phenomenon. The partner antibiotic in the sulbactam combination (e.g., ampicillin) may be highly effective against the co-infecting pathogen, rapidly reducing the total bacterial burden and allowing the host's immune response to more effectively target the remaining A. baumannii. Alternatively, there may be complex microbial interactions, such as antagonism, where the elimination of one species creates a less favorable environment for the other. This finding is clinically significant, suggesting that the presence of a co-pathogen should not be a deterrent to using a sulbactam-based regimen for a known A. baumannii infection and may, in fact, be associated with a better microbiological outcome for that specific organism. The study also reinforced the importance of aggressive dosing, finding that a daily sulbactam dose of at least 8 grams was associated with the best clinical and microbiological efficacy.[56]

8.0 Global Regulatory Landscape

The approval and availability of sulbactam-containing products vary across different international regulatory agencies, reflecting different timelines of submission, regional medical needs, and local pharmaceutical markets.

8.1 United States Food and Drug Administration (FDA)

The FDA has a long history with sulbactam, beginning with its initial combination products and culminating in the recent approval of a novel, targeted therapy.

• Ampicillin/Sulbactam (Unasyn®): The combination of ampicillin sodium and sulbactam sodium was first approved by the FDA on December 31, 1986, with Pfizer as the manufacturer.[59] It is indicated for skin and skin structure infections, intra-abdominal infections, and gynecological infections.[18] Following the expiration of its market exclusivity, numerous generic versions have been approved, with the first approvals occurring in the early 2000s.[59]
• Sulbactam/Durlobactam (Xacduro®): This co-packaged product represents a major recent milestone. It was approved on May 23, 2023, for the treatment of adults with HABP and VABP caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex.[4] The development and review process was expedited, reflecting the urgent unmet medical need. The FDA granted the application several key designations: Fast Track, Priority Review, and Qualified Infectious Disease Product (QIDP).[34] The approval was strongly supported by the FDA's Antimicrobial Drugs Advisory Committee, which voted unanimously (12-0) in favor of its approval based on a favorable benefit-risk assessment.[32]

8.2 European Medicines Agency (EMA) and National Authorisations in Europe

In the European Union, the regulatory status of sulbactam products is managed at the national level rather than through a centralized EMA marketing authorization.[27] Combination products like cefoperazone/sulbactam (e.g., Sulperazon®) are authorized in several member states, including Poland, Slovakia, Bulgaria, the Czech Republic, and Italy.[27]

The EMA's role involves harmonizing safety information across the EU through Periodic Safety Update Report Single Assessments (PSUSAs). These assessments review cumulative safety data for active substances and can lead to updates in the product information for all nationally authorized medicines containing them. A 2015 PSUSA for ampicillin/sulbactam, for example, led to the recommendation to add warnings for drug-induced liver injury and to include adverse reactions such as angioedema, erythema, and urticaria in the product labeling.[50] Ampicillin/sulbactam is also referenced in EMA documents related to the categorization of antibiotics for veterinary use, indicating its broad presence in the European pharmaceutical market.[63]

8.3 Therapeutic Goods Administration (TGA) in Australia

Specific TGA approval documents for sulbactam-containing products were not identified in the provided materials.[64] The TGA is the Australian government authority responsible for regulating therapeutic goods, which must be entered on the Australian Register of Therapeutic Goods (ARTG) before they can be legally supplied.[66] However, evidence from a TGA Freedom of Information release shows that "Ampicillin/Sulbactam" was accessed through the Special Access Scheme (SAS) in both 2019 and 2020.[69] The SAS provides a pathway for health practitioners to access therapeutic goods that are not on the ARTG for individual patients on a case-by-case basis. This suggests that while ampicillin/sulbactam may not have full marketing authorization in Australia, it is recognized as a necessary therapeutic option and is utilized in clinical practice for specific patient needs.

9.0 Future Directions and Analysis of Recent Clinical Research

The clinical development landscape for Sulbactam is active and evolving, driven by the urgent need for new therapies against multidrug-resistant organisms. Recent and ongoing clinical trials are providing high-quality evidence to define its modern role, particularly in the treatment of CRAB and in special populations.

9.1 The ATTACK Trial: A Paradigm Shift in CRAB Treatment

The ATTACK trial (NCT03894046) was the pivotal Phase 3 study that established the efficacy and safety of sulbactam/durlobactam and led to its FDA approval.[61]

• Study Design: This was a multicenter, randomized, active-controlled, non-inferiority trial. It enrolled hospitalized adults with serious infections, predominantly HABP/VABP, caused by carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRAB).[37] Patients were randomized to receive either sulbactam/durlobactam or colistin, a historical last-resort agent for CRAB. Importantly, both treatment arms also received imipenem/cilastatin as background therapy to cover other potential nosocomial pathogens.[61]
• Efficacy Outcomes: The primary endpoint was 28-day all-cause mortality. In the primary analysis population, sulbactam/durlobactam demonstrated non-inferiority to colistin. The mortality rate was numerically lower in the sulbactam/durlobactam group at 19% (12 of 63 patients) compared to 32% (20 of 62 patients) in the colistin group.[61] Furthermore, sulbactam/durlobactam was superior in achieving the secondary endpoint of clinical cure at the test-of-cure visit (62% vs. 40%).[71]
• Safety Outcomes: The trial revealed a stark and clinically meaningful difference in safety profiles. The incidence of nephrotoxicity, a well-known and dose-limiting toxicity of colistin, was significantly lower in the sulbactam/durlobactam group (13%) compared to the colistin group (38%).[70]

The results of the ATTACK trial represent a practice-changing development. They provide robust evidence that sulbactam/durlobactam is not only an effective treatment for life-threatening CRAB infections but also a substantially safer alternative to colistin, positioning it as a new standard of care for this indication.

Table 3: Key Outcomes of the Phase 3 ATTACK Trial (Sulbactam/Durlobactam vs. Colistin)

Endpoint	Sulbactam/Durlobactam Group	Colistin Group	Result (Difference, 95% CI)	Interpretation
28-Day All-Cause Mortality (Primary)	19.0% (12/63)	32.3% (20/62)	-13.2% (-30.0% to 3.5%)	Met criteria for non-inferiority, with a strong trend toward lower mortality.
Clinical Cure at Test-of-Cure	62%	40%	Statistically significant ($p=0.016$)	Superior clinical response with sulbactam/durlobactam.
Nephrotoxicity	13% (12/91)	38% (32/85)	Statistically significant ($p<0.001$)	Markedly superior renal safety profile for sulbactam/durlobactam.

9.2 Emerging Data on Pediatric Pharmacokinetics and Safety

While sulbactam/durlobactam is currently approved for adults, its potential use in children is a critical area of investigation, as therapeutic options for CRAB infections in pediatric patients are extremely limited.

• Ongoing Clinical Trial (NCT06801223): A multicenter, open-label, Phase 1b study is actively assessing the pharmacokinetics, safety, and tolerability of sulbactam/durlobactam in hospitalized pediatric patients from birth to less than 18 years of age with suspected or confirmed A. baumannii infections.[72] The primary goal is to collect the necessary data to establish safe and effective pediatric dosing regimens across different age cohorts.[72]
• Early Clinical Evidence: Although formal trial results are pending, a published case report details the successful compassionate use of a sulbactam/durlobactam-based regimen to treat CRAB sepsis with cutaneous involvement in a 10-month-old infant with acute leukemia.[57] This case provides preliminary evidence of both potential efficacy and safety in a very young, critically ill patient.
• Pharmacokinetic Modeling: To inform pediatric dosing strategies, researchers have conducted population PK modeling using existing data for sulbactam in children. These analyses suggest that to achieve the necessary PK/PD targets against A. baumannii, higher dosing regimens, particularly when administered as extended infusions, will likely be required in pediatric patients compared to standard dosing for more susceptible pathogens.[75]

9.3 Ongoing Investigations and Unanswered Questions

The research landscape for sulbactam continues to expand. A clinical trial (NCT07118384) is planned to directly compare the clinical efficacy of two widely used combinations, ampicillin/sulbactam and cefoperazone/sulbactam, for treating MDR A. baumannii infections in critically ill patients, which could help clarify their relative positioning.[76] Additionally, a real-world observational study (NCT06746883) is underway to further evaluate the safety of sulbactam/durlobactam, with a specific focus on the risk of hypersensitivity reactions in a broader adult population.[77] A key unanswered question remains the optimal partner agent(s) to use with sulbactam/durlobactam in cases of polymicrobial infections or for potential synergy against highly resistant CRAB strains.[71]

10.0 Expert Analysis and Strategic Recommendations

Sulbactam's trajectory from a general-purpose β-lactamase inhibitor to a cornerstone agent in the fight against a critical multidrug-resistant pathogen is a testament to the value of understanding and leveraging a drug's fundamental pharmacological properties. A nuanced analysis reveals both its considerable strengths and its inherent limitations, guiding its optimal placement within antimicrobial stewardship programs.

10.1 Synthesis of Strengths and Limitations

• Strengths:

1. Dual Mechanism of Action: The combination of broad β-lactamase inhibition and intrinsic antibacterial activity against key pathogens like Acinetobacter provides a unique therapeutic advantage.
2. Proven Clinical Utility: Decades of use have established the efficacy and safety of ampicillin/sulbactam for a wide range of common polymicrobial infections.
3. Targeted Efficacy against CRAB: The sulbactam/durlobactam combination provides a highly effective, evidence-based therapy for life-threatening CRAB pneumonia, addressing a major unmet medical need.
4. Superior Safety Profile: Compared to last-resort agents like colistin, sulbactam/durlobactam offers a significantly lower risk of nephrotoxicity, a major clinical benefit in critically ill patients.
5. Favorable Pharmacokinetics: The well-matched pharmacokinetic profile of sulbactam and ampicillin simplifies dosing and ensures a consistent therapeutic ratio, even in patients with renal dysfunction.

• Limitations:

1. Gaps in Spectrum: Sulbactam is not effective against all β-lactamases, notably metallo-β-lactamases (MBLs), which are an emerging threat globally.
2. Hypersensitivity Risk: As a penicillin derivative, it carries the risk of cross-reactivity in patients with a history of penicillin allergy, which can limit its use.
3. Risk of Collateral Damage: Like all broad-spectrum antibiotics, its use contributes to the risk of C. difficile-associated diarrhea and the selection of other resistant organisms.
4. Emerging Resistance: Resistance to ampicillin/sulbactam is increasing among common pathogens like E. coli, necessitating reliance on local susceptibility data.

10.2 Recommendations for Antimicrobial Stewardship Programs

To preserve the utility of sulbactam and its combinations, antimicrobial stewardship programs should implement clear, evidence-based guidelines for their use.

1. Position Ampicillin/Sulbactam as a Workhorse, Not a Panacea: Ampicillin/sulbactam should remain a first-line or preferred agent for empiric treatment of community-associated intra-abdominal infections, diabetic foot infections (without Pseudomonas risk), and human/animal bite wounds. However, its use for hospital-acquired infections, particularly those where resistant Gram-negative pathogens like E. coli are prevalent, must be guided by up-to-date local antibiograms.
2. Restrict and Protect Sulbactam/Durlobactam: Xacduro® should be a restricted antimicrobial, requiring infectious disease consultation or pre-authorization. Its use should be reserved for documented or highly suspected infections caused by carbapenem-resistant A. baumannii. This will be crucial to delay the emergence of resistance to this vital new agent. Given its superior safety profile, it should be the preferred agent over colistin for susceptible CRAB infections.
3. Promote PK/PD-Optimized Dosing: Stewardship programs should actively educate prescribers on the rationale for high-dose, extended-infusion regimens of ampicillin/sulbactam when used for documented CRAB infections. This ensures that when this older agent is used as a last resort, it is dosed in a manner that maximizes its potential for efficacy.

10.3 Concluding Remarks

The clinical journey of Sulbactam is a compelling narrative in modern pharmacology. It has evolved from being viewed simply as an "add-on" to being recognized for its own potent, targeted bactericidal activity. This evolution was not the result of discovering a new molecule, but of reinvestigating an old one with new scientific tools and a clear clinical focus. The success of sulbactam/durlobactam validates the strategy of developing "protector" molecules for established agents and highlights the potential that may lie dormant in our existing antimicrobial armamentarium. Sulbactam's story serves as a powerful reminder that in the relentless battle against antimicrobial resistance, innovation can come not only from new discoveries but also from the intelligent and strategic optimization of proven therapeutic assets. Its future is secure, not as a historical footnote, but as an essential component of contemporary infectious disease therapy.

Works cited

1. β-Lactams and β-Lactamase Inhibitors: An Overview - PMC - NIH, accessed October 31, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4968164/
2. What is the mechanism of Sulbactam sodium? - Patsnap Synapse, accessed October 31, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-sulbactam-sodium
3. Old and New Beta-Lactamase Inhibitors: Molecular Structure, Mechanism of Action, and Clinical Use - MDPI, accessed October 31, 2025, https://www.mdpi.com/2079-6382/10/8/995
4. Sulbactam - Wikipedia, accessed October 31, 2025, https://en.wikipedia.org/wiki/Sulbactam
5. Sulbactam | C8H11NO5S | CID 130313 - PubChem - NIH, accessed October 31, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Sulbactam
6. www.sigmaaldrich.com, accessed October 31, 2025, https://www.sigmaaldrich.com/US/en/product/sigma/s9701#:~:text=Sulbactam%20acts%20as%20an%20irreversible,It%20exhibits%20limited%20antimicrobial%20activity.
7. Sulbactam – Knowledge and References – Taylor & Francis, accessed October 31, 2025, https://taylorandfrancis.com/knowledge/Medicine_and_healthcare/Pharmaceutical_medicine/Sulbactam/
8. Sulbactam: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed October 31, 2025, https://go.drugbank.com/drugs/DB09324
9. Molecular Mechanisms of Sulbactam Antibacterial Activity and Resistance Determinants in Acinetobacter baumannii - PMC - NIH, accessed October 31, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4325763/
10. Sulbactam 68373-14-8 - Sigma-Aldrich, accessed October 31, 2025, https://www.sigmaaldrich.com/US/en/product/sigma/s9701
11. Sulbactam (CAS 68373-14-8) - Cayman Chemical, accessed October 31, 2025, https://www.caymanchem.com/product/15024/sulbactam
12. Sulbactam 68373-14-8 | TCI AMERICA - TCI Chemicals, accessed October 31, 2025, https://www.tcichemicals.com/US/en/p/S0868
13. Sulbactam - brand name list from Drugs.com, accessed October 31, 2025, https://www.drugs.com/ingredient/sulbactam.html
14. Sulbactam | CAS 68373-14-8 | SCBT - Santa Cruz Biotechnology, accessed October 31, 2025, https://www.scbt.com/p/sulbactam-68373-14-8
15. Sulbactam (250 mg) (COLD SHIPMENT REQUIRED) - USP Store, accessed October 31, 2025, https://store.usp.org/product/1623670
16. UNASYN® (ampicillin sodium and sulbactam sodium) For Injection, USP - Pfizer, accessed October 31, 2025, https://labeling.pfizer.com/showlabeling.aspx?id=617
17. Ampicillin and sulbactam (injection route) - Side effects & uses - Mayo Clinic, accessed October 31, 2025, https://www.mayoclinic.org/drugs-supplements/ampicillin-and-sulbactam-injection-route/description/drg-20072723
18. UNASYN® (ampicillin sodium/sulbactam sodium) To reduce the development of drug-resistant bacteria and maintain the effectiven - accessdata.fda.gov, accessed October 31, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050608s047lbl.pdf
19. Xacduro (sulbactam and durlobactam (co-packaged)) FDA Approval History - Drugs.com, accessed October 31, 2025, https://www.drugs.com/history/xacduro.html
20. XACDURO (sulbactam and durlobactam) - This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed October 31, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216974Orig1s000Correctedlbl.pdf
21. UNASYN® - accessdata.fda.gov, accessed October 31, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050608s029lbl.pdf
22. Sulbactam: a beta-lactamase inhibitor. | DrugBank Online, accessed October 31, 2025, https://go.drugbank.com/articles/A263301
23. Ampicillin/Sulbactam - StatPearls - NCBI Bookshelf, accessed October 31, 2025, https://www.ncbi.nlm.nih.gov/books/NBK526117/
24. UNASYN® (ampicillin sodium, sulbactam sodium) Dosage and Administration | Pfizer Medical - US, accessed October 31, 2025, https://www.pfizermedical.com/unasyn/dosage-admin
25. Ampicillin / Sulbactam Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed October 31, 2025, https://www.drugs.com/dosage/ampicillin-sulbactam.html
26. Ampicillin/Sulbactam Monograph for Professionals - Drugs.com, accessed October 31, 2025, https://www.drugs.com/monograph/ampicillin-sulbactam.html
27. cefoperazone- sulbactam PSUSA-00000598-202101-Line listing - European Medicines Agency, accessed October 31, 2025, https://www.ema.europa.eu/en/documents/psusa/cefoperazone-sulbactam-list-nationally-authorised-medicinal-products-psusa00000598202101_en.pdf
28. Uses of Cefoperazone Sulbactam - Vinmec, accessed October 31, 2025, https://www.vinmec.com/eng/blog/uses-of-cefoperazone-sulbactam-en
29. Sulbactam/Cefoperazone 1:1 and 1:2 - MAGNEX®/MAGNEX® FORTE Injection - Pfizer, accessed October 31, 2025, https://labeling.pfizer.com/ShowLabeling.aspx?id=14800
30. Comparison of Efficacy of Cefoperazone/Sulbactam and Imipenem/Cilastatin for Treatment of Acinetobacter Bacteremia - PMC - NIH, accessed October 31, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2687582/
31. Proposal to the 2025 WHO EML Expert Committee on AMR/AWaRe Classification regarding Cefoperazone/Sulbactam, accessed October 31, 2025, https://cdn.who.int/media/docs/default-source/2025-eml-expert-committee/other-matters/o.2_cefoperazone-sulbactam.pdf?sfvrsn=3aa8c360_7
32. FDA approves antibiotic combination for hospital-acquired pneumonia - CIDRAP, accessed October 31, 2025, https://www.cidrap.umn.edu/antimicrobial-stewardship/fda-approves-antibiotic-combination-hospital-acquired-pneumonia
33. Sulbactam plus durlobactam: a new addition to antibacterial therapies – by Ursula Theuretzbacher - GARDP Revive, accessed October 31, 2025, https://revive.gardp.org/sulbactam-plus-durlobactam-a-new-addition-to-antibacterial-therapies/
34. Sulbactam-Durlobactam Unanimously Recommended for Approval by FDA Advisory Committee - Zai Lab, accessed October 31, 2025, https://ir.zailaboratory.com/zh-hant/news-releases/news-release-details/sulbactam-durlobactam-unanimously-recommended-approval-fda/
35. FDA Approves New Treatment for Pneumonia Caused by Certain Difficult-to-Treat Bacteria, accessed October 31, 2025, https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-pneumonia-caused-certain-difficult-treat-bacteria
36. Sulbactam-durlobactam: uses, dosing, warnings, adverse events, interactions - MedCentral, accessed October 31, 2025, https://www.medcentral.com/drugs/monograph/186799-323037/sulbactam-durlobactam-intravenous
37. FDA News: Issue 17-1 August 2023 - ASCPT, accessed October 31, 2025, https://www.ascpt.org/Resources/ASCPT-News/View/ArticleId/28314/FDA-News-Issue-17-1-August-2023
38. High-dose Sulbactam Treatment for Ventilator-Associated Pneumonia Caused by Carbapenem-Resistant Acinetobacter Baumannii - Acute and Critical Care, accessed October 31, 2025, https://www.accjournal.org/journal/view.php?doi=10.4266/kjccm.2015.00703
39. Sulbactam for carbapenem-resistant Acinetobacter baumannii infections: a literature review - PMC - NIH, accessed October 31, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11992565/
40. Unasyn, (ampicillin-sulbactam) dosing, indications, interactions, adverse effects, and more, accessed October 31, 2025, https://reference.medscape.com/drug/unasyn-ampicillin-sulbactam-342476
41. UNASYN IM/IV - Pfizer, accessed October 31, 2025, https://labeling.pfizer.com/ShowLabeling.aspx?id=12115
42. What is the recommended dose of ampicillin-sulbactam? - Dr.Oracle AI, accessed October 31, 2025, https://www.droracle.ai/articles/241643/dose-of-ampisulbactam
43. Ampicillin and Sulbactam Injection: MedlinePlus Drug Information, accessed October 31, 2025, https://medlineplus.gov/druginfo/meds/a693021.html
44. Ampicillin/Sulbactam (Unasyn): Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD, accessed October 31, 2025, https://www.webmd.com/drugs/2/drug-78232/unasyn-intravenous/details
45. What are the side effects of Sulbactam sodium? - Patsnap Synapse, accessed October 31, 2025, https://synapse.patsnap.com/article/what-are-the-side-effects-of-sulbactam-sodium
46. Ampicillin and sulbactam Uses, Side Effects & Warnings - Drugs.com, accessed October 31, 2025, https://www.drugs.com/mtm/ampicillin-and-sulbactam.html
47. Sulbactam: Uses, Side Effects and Medicines - MrMed, accessed October 31, 2025, https://www.mrmed.in/molecule/sulbactam
48. Sulbactam-Durlobactam: Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed October 31, 2025, https://www.rxlist.com/sulbactam-durlobactam/generic-drug.htm
49. Ampicillin and Sulbactam for Injection, USP, accessed October 31, 2025, https://labeling.pfizer.com/ShowLabeling.aspx?id=4344
50. Active substance: Ampicillin / Sulbactam Regulatory outcome: variation, accessed October 31, 2025, https://www.ema.europa.eu/en/documents/psusa/ampicillin-sulbactam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000197201502_en.pdf
51. Unasyn Disease Interactions - Drugs.com, accessed October 31, 2025, https://www.drugs.com/disease-interactions/ampicillin-sulbactam,unasyn.html
52. Ampicillin/Sulbactam drug interactions - Litt's Drug Eruption and Reaction Database, accessed October 31, 2025, https://www.drugeruptiondata.com/drug/id/2255
53. Ampicillin/sulbactam and Alcohol/Food Interactions - Drugs.com, accessed October 31, 2025, https://www.drugs.com/food-interactions/ampicillin-sulbactam.html
54. Risk Factors for Recovery of Ampicillin-Sulbactam-Resistant Escherichia coli in Hospitalized Patients | Antimicrobial Agents and Chemotherapy - ASM Journals, accessed October 31, 2025, https://journals.asm.org/doi/10.1128/aac.44.4.1004-1009.2000
55. IDSA 2024 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections, accessed October 31, 2025, https://www.idsociety.org/practice-guideline/amr-guidance/
56. Evaluation of the efficacy of sulbactam combination therapy for ..., accessed October 31, 2025, https://journals.asm.org/doi/10.1128/spectrum.03355-24
57. Sulbactam-durlobactam combination therapy for carbapenem-resistant Acinetobacter baumannii sepsis with cutaneous involvement in an infant with acute monocytic leukemia: A case report - PubMed Central, accessed October 31, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12443841/
58. Durlobactam in the Treatment of Multidrug-Resistant Acinetobacter baumannii Infections: A Systematic Review - MDPI, accessed October 31, 2025, https://www.mdpi.com/2077-0383/11/12/3258
59. Generic Unasyn Availability - Drugs.com, accessed October 31, 2025, https://www.drugs.com/availability/generic-unasyn.html
60. www.ncbi.nlm.nih.gov, accessed October 31, 2025, https://www.ncbi.nlm.nih.gov/books/NBK526117/#:~:text=The%20ampicillin%2Fsulbactam%20combination%20has,abdominal%20infections%2C%20and%20gynecological%20infections.
61. Sulbactam/durlobactam - Wikipedia, accessed October 31, 2025, https://en.wikipedia.org/wiki/Sulbactam/durlobactam
62. PSUSA/00000197/202402 - periodic safety update report single assessment, accessed October 31, 2025, https://www.ema.europa.eu/en/medicines/psusa/psusa-00000197-202402
63. AMEG 2018 - Categorisation of antibiotics - European Medicines Agency, accessed October 31, 2025, https://www.ema.europa.eu/en/documents/report/categorisation-antibiotics-european-union-answer-request-european-commission-updating-scientific-advice-impact-public-health-animal-health-use-antibiotics-animals_en.pdf
64. AusPAR: Nivolumab and ipilimumab - Therapeutic Goods Administration (TGA), accessed October 31, 2025, https://www.tga.gov.au/sites/default/files/auspar-nivolumab-ipilimumab-210427.docx
65. Australian Register of Therapeutic Goods (ARTG) | Therapeutic ..., accessed October 31, 2025, https://www.tga.gov.au/products/australian-register-therapeutic-goods-artg
66. TGA – Therapeutic Goods Administration - Healthdirect, accessed October 31, 2025, https://www.healthdirect.gov.au/partners/tga-therapeutic-goods-administration
67. Therapeutic Goods Administration (TGA) - Digital Health Developer Portal, accessed October 31, 2025, https://developer.digitalhealth.gov.au/standards/organisation/therapeutic-goods-administration-tga
68. Therapeutic Goods Administration - Wikipedia, accessed October 31, 2025, https://en.wikipedia.org/wiki/Therapeutic_Goods_Administration
69. SAS-A, accessed October 31, 2025, https://www.tga.gov.au/sites/default/files/foi-3426-01.pdf
70. Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii–calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK) - Northwestern Scholars, accessed October 31, 2025, https://www.scholars.northwestern.edu/en/publications/efficacy-and-safety-of-sulbactamdurlobactam-versus-colistin-for-t
71. Sulbactam-Durlobactam: A New Weapon to ATTACK Acinetobacter baumannii, accessed October 31, 2025, https://www.jwatch.org/na56537/2023/09/11/sulbactam-durlobactam-new-weapon-attack-acinetobacter
72. NCT06801223 | A Study to Assess Sulbactam-durlobactam in Pediatric Patients With Acinetobacter Baumannii-calcoaceticus Complex Infection | ClinicalTrials.gov, accessed October 31, 2025, https://www.clinicaltrials.gov/study/NCT06801223
73. A Study to Assess Sulbactam-durlobactam in Pediatric Patients With Acinetobacter Baumannii-calcoaceticus Complex Infection - UCLA Health, accessed October 31, 2025, https://www.uclahealth.org/clinical-trials/study-assess-sulbactam-durlobactam-pediatric-patients-with
74. (PDF) Sulbactam-durlobactam combination therapy for carbapenem-resistant Acinetobacter baumannii sepsis with cutaneous involvement in an infant with acute monocytic leukemia: A case report - ResearchGate, accessed October 31, 2025, https://www.researchgate.net/publication/395279209_Sulbactam-durlobactam_combination_therapy_for_carbapenem-resistant_Acinetobacter_baumannii_sepsis_with_cutaneous_involvement_in_an_infant_with_acute_monocytic_leukemia_A_case_report
75. Population Pharmacokinetic Analysis and Pharmacodynamic Evaluation of Sulbactam in Pediatric Patients: Dosing Suggestions for Acinetobacter baumannii Infections - PMC - PubMed Central, accessed October 31, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12123189/
76. Study Details | NCT07118384 | Comparison of the Clinical Efficacy of Ampicillin/Sulbactam and Cefoperazone/Sulbactam Against Multidrug Resistant Acinetobacter Baumannii Infections in Critically Ill Patients | ClinicalTrials.gov, accessed October 31, 2025, https://clinicaltrials.gov/study/NCT07118384
77. A Study to Assess the Safety and Risk of Hypersensitivity Reactions of Sulbactam-durlobactam in Adults With Acinetobacter Baumannii-calcoaceticus (ABC) Complex Infection | Clinical Research Trial Listing - CenterWatch, accessed October 31, 2025, https://www.centerwatch.com/clinical-trials/listings/NCT06746883/a-study-to-assess-the-safety-and-risk-of-hypersensitivity-reactions-of-sulbactam-durlobactam-in-adults-with-acinetobacter-baumannii-calcoaceticus-abc-complex-infection
78. From clinical trials to daily practice: how to adequately administer sulbactam-durlobactam? alone or combined with imipenem? - PubMed, accessed October 31, 2025, https://pubmed.ncbi.nlm.nih.gov/40920473/